NEW YORK, April 27, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on AKER, ATRS, BAX, and BDX which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, April 26, 2018, US markets saw broad based gains with seven
On Thursday, shares in Thorofare, New Jersey headquartered Akers Biosciences Inc. recorded a trading volume of 8.45 million shares. The stock ended the session 11.70% higher at $0.55. The Company's shares have gained 131.38% over the previous three months. The stock is trading below its 50-day moving average by 13.09%. Moreover, shares of Akers Biosciences, which together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the US and internationally, have a Relative Strength Index (RSI) of 42.48. Get the full research report on AKER for free by clicking below at:
Ewing, New Jersey headquartered Antares Pharma Inc.'s stock closed the day 2.63% higher at $2.34 with a total trading volume of 328,576 shares. The Company's shares have advanced 9.86% in the past month. The stock is trading above its 50-day moving average by 1.82%. Additionally, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 55.34. Free research on ATRS can be accessed at:
Shares in Deerfield, Illinois headquartered Baxter International Inc. recorded a trading volume of 5.45 million shares, which was above their three months average volume of 3.26 million shares. The stock ended yesterday's trading session 5.22% higher at $69.99. The Company's shares have advanced 25.90% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 5.39% and 8.14%, respectively. Furthermore, shares of Baxter, which provides a portfolio of healthcare products, have an RSI of 65.29. Sign up today for the free research report on BAX at:
Becton, Dickinson and Co.
Franklin Lakes, New Jersey-based Becton, Dickinson and Co.'s stock finished Thursday's session 1.48% higher at $232.89 with a total trading volume of 882,831 shares. The Company's shares have advanced 29.52% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 5.06% and 8.80%, respectively. Additionally, shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, have an RSI of 61.34.
On April 10th, 2018, research firm Citigroup upgraded the Company's stock rating from 'Neutral' to 'Buy'. Wall St. Equities' research coverage also includes the downloadable free report on BDX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-medical-supplies-equities----akers-biosciences-antares-pharma-baxter-and-becton-dickinson-and-co-300637935.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...
Drug interactions checker can be used to check over the counter ( OTC) and regular prescription ...
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...View All